Eisai, Takeda Follow Differing Japan Treatments For Alzheimer’s Disease
This article was originally published in PharmAsia News
Eisai and Takeda Pharmaceutical have stepped in to fill a vacuum of drugs to treat Alzheimer’s disease, each working on treatments either to halt development of the disease or to reverse it.
You may also be interested in...
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.